PARADIGM BIOPHARMACEUTICALS LIMITED

INVESTOR PRESENTATION - PARADIGM BIOPHARMACEUTICALS LIMITED

ASX:PAR

PARADIGM BIOPHARMACEUTICALS LIMITED

Health Care

Paradigm Biopharmaceuticals Limited (PAR) is an Australian biopharmaceutical company focused on repurposing the drug 'pentosan polysulphate sodium' (PPS) for the treatment of bone marrow edema. Paradigm is targeting addressable markets with the aim to use the shortened development pathway utilising repurposed drugs.

Market Cap

633.79m

Price at Close

$2.82

4w avg. Volume

1.73m

4w avg. Turnover

$5.37m

Announcements
announcementt+2 movementdate
  • MPS RECEIVES CRITICAL APPROVALS AND FEEDBACK FROM AGENCIES

    Progress Report · Market sensitive

  • -0.35%

    10 Aug 2020

-0.35%

10 Aug 2020
  • Quarterly Activities Report

    Commitments test entity quarterly reports · Market sensitive

  • -2.30%

    31 Jul 2020

-2.30%

31 Jul 2020
  • EAP - 65% PAIN REDUCTION IN 10 OA PATIENTS IN USA

    Progress Report · Market sensitive

  • -5.86%

    29 Jul 2020

-5.86%

29 Jul 2020
  • Appendix 4C - quarterly

    Commitments test entity quarterly reports · Market sensitive

  • -5.86%

    29 Jul 2020

-5.86%

29 Jul 2020
  • Cleansing Notice and Appendix 3G

    Issued Capital

  • +12.94%

    17 Jul 2020

+12.94%

17 Jul 2020
  • NEW FINANCIAL YEAR UPDATE

    Progress Report · Market sensitive

  • +3.53%

    14 Jul 2020

+3.53%

14 Jul 2020
  • Initial Director's Interest Notice

    Shareholder Details

  • -0.61%

    07 Jul 2020

-0.61%

07 Jul 2020
  • Paradigm adds Dr Donna Skerrett as Executive Director

    Company Administration

  • -3.71%

    02 Jul 2020

-3.71%

02 Jul 2020
  • Cleansing Notice and Appendix 2A

    Issued Capital

  • -7.08%

    26 Jun 2020

-7.08%

26 Jun 2020
  • Final Director's Interest Notice

    Shareholder Details

  • -7.08%

    26 Jun 2020

-7.08%

26 Jun 2020
Market Data

Current Price

$2.82

52WK HIGH

$4.5

52WK LOW

$1.08

1YR RETURN

+97.20%

1YR RETURN VS. SECTOR

+68.40%

90 DAY RETURN

+23.68%

ASX RANK

313

/2,032

SECTOR RANK

6

/47

SHARES OUTSTANDING

224.75m
ASX:PAR

PARADIGM BIOPHARMACEUTICALS LIMITED

Health Care

Paradigm Biopharmaceuticals Limited (PAR) is an Australian biopharmaceutical company focused on repurposing the drug 'pentosan polysulphate sodium' (PPS) for the treatment of bone marrow edema. Paradigm is targeting addressable markets with the aim to use the shortened development pathway utilising repurposed drugs.

Market Cap

633.79m

Price at Close

$2.82

4w avg. Volume

1.73m

4w avg. Turnover

$5.37m

ASX:PAR is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Support

Ask Fresh

Archive
Contact Us

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

(03) 9028 2888

deals@freshequities.com

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.